MBRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Moleculin Biotech Inc (MBRX) is not a strong buy for a beginner, long-term investor at this time. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to suggest an immediate buying opportunity. A hold strategy is recommended until there are clearer signs of improvement in the company's fundamentals or market sentiment.
The technical indicators suggest a bearish trend. The MACD histogram is negative and contracting, RSI is neutral at 25.43, and moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 2.446), with resistance levels far above the current price, indicating limited upward momentum in the short term.
Analysts maintain a Buy rating, and the Phase 2b/3 MIRACLE trial is progressing as planned, with initial results expected in Q1 2026.
The stock recently underwent a 1-for-25 reverse split, which often signals financial instability. Financial performance is poor, with no revenue, significant net losses, and a sharp decline in EPS. There is no recent news or significant trading activity from insiders, hedge funds, or Congress to suggest confidence in the stock.
In Q3 2025, the company reported no revenue growth (0% YoY), a net loss of -$25.4M (up 139.79% YoY), and a sharp decline in EPS to -17.02 (-76.13% YoY). Gross margin remains at 0%. Overall, the financials indicate weak performance and no signs of profitability.
Analysts have lowered price targets significantly following the reverse split. Roth Capital reduced the target from $300 to $31, and H.C. Wainwright adjusted it from $4 to $22. Both maintain a Buy rating, but the drastic price target reductions highlight uncertainty.
